Celldex

HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the…

<!-- Name:DistributionId Value:8839036 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON,…

-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose…

HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th…

HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements…

- 95% complete response rate after single dose of CDX-0159 -- Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief -- Median duration of…